MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Kodu・Aktsiate loetelu・AbCellera Biologics Inc

AbCellera Biologics Inc

Suletud

SektorTervishoid

3.3 -3.23

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.22

Max

3.39

Põhinäitajad
By Trading Economics
Sissetulek	48M -8.9M
Müük	36M 45M
Kasumimarginaal	-19.942
Töötajad	562
EBITDA	22M -18M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+65.91% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	87M 994M
Eelmine avamishind	6.53
Eelmine sulgemishind	3.3

Uudiste sentiment

By Acuity

50%

151 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.99 / 2.635 Toetus ja vastupanu

AbCellera Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2026, 17:26 UTC

Uudisväärsed sündmused

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. apr 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Market Talk Roundup: Latest on U.S. Politics

7. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. apr 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:15 UTC

Market Talk

Uudisväärsed sündmused

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. apr 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. apr 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. apr 2026, 23:01 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. apr 2026, 22:58 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

7. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. apr 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. apr 2026, 19:17 UTC

Uudisväärsed sündmused

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. apr 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. apr 2026, 18:41 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. apr 2026, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. apr 2026, 18:39 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. apr 2026, 18:24 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. apr 2026, 16:21 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

AbCellera Biologics Inc Prognoos

Hinnasiht

By TipRanks

65.91% tõus

12 kuu keskmine prognoos

Keskmine 5.84 USD 65.91%

Kõrge 7 USD

Madal 3.52 USD

Põhineb 4 Wall Streeti analüütiku instrumendi AbCellera Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi AbCellera Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.99 / 2.635Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

151 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.